1. Search Result
Search Result
Results for "

Fxa

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

2

Peptides

1

Inhibitory Antibodies

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-134686

    Factor Xa Thrombin Cardiovascular Disease
    Edoxaban impurity 4 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention .
    Edoxaban impurity 4
  • HY-10268S

    Factor Xa Cardiovascular Disease
    Betrixaban-d6 is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor[1].
    Betrixaban-d6
  • HY-10758

    Factor Xa Cardiovascular Disease
    FXa-IN-1 is a FXa inhibitor (IC50: 3 nM, Ki: 0.7 nM) with respectable oral bioavailability and half-life in vivo. FXa-IN-1 can be used for thromboembolic disorders .
    <em>FXa</em>-IN-1
  • HY-76409

    FXV673 hydrochloride

    Factor Xa Inflammation/Immunology
    Otamixaban (FXV673) is a potent, selective, rapid-acting, competitive, and reversible fXa inhibitor (Ki=0.5 nM) that effectively inhibits both free and prothrombinase-bound fXa .
    Otamixaban hydrochloride
  • HY-100652A

    Factor Xa Cardiovascular Disease
    O-Desmethyl apixaban sulfate sodium is a major circulating metabolite of Apixaban in humans. O-Desmethyl apixaban sulfate sodium inhibits factor X (FXa) with a Ki of 58 μM .
    O-Desmethyl apixaban sulfate sodium
  • HY-10264
    Edoxaban
    4 Publications Verification

    DU-176

    Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .
    Edoxaban
  • HY-10264B
    Edoxaban tosylate monohydrate
    4 Publications Verification

    DU-176b monohydrate

    Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .
    Edoxaban tosylate monohydrate
  • HY-10264A
    Edoxaban tosylate
    4 Publications Verification

    DU-176b

    Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research .
    Edoxaban tosylate
  • HY-10264C

    DU-176 hydrochloride

    Factor Xa Thrombin Cardiovascular Disease
    Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research .
    Edoxaban hydrochloride
  • HY-76971

    Factor Xa Cardiovascular Disease
    Dechloro Rivaroxaban is a highly selective, orally active inhibitor of Factor Xa. Dechloro Rivaroxaban inhibits human free FXa with a Ki of 0.4 nM. Dechloro Rivaroxaban inhibits prothrombinase activity and fibrin-associated FXa activity with IC50s of 2.1 nM and 92 nM, respectively .
    Dechloro Rivaroxaban
  • HY-122592

    Factor Xa Cardiovascular Disease
    Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC50 of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research .
    Zifaxaban
  • HY-119124

    D21-2393

    Drug Metabolite Metabolic Disease
    Edoxaban M4, an active metabolite of Edoxaban, shows reproducible, but concentration-dependent matrix effects. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor .
    Edoxaban M4
  • HY-14853

    YM150

    Factor Xa Ser/Thr Protease Cardiovascular Disease
    Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC50 of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects .
    Darexaban
  • HY-70035

    FXV673

    Factor Xa Cardiovascular Disease
    Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.
    Otamixaban
  • HY-50903
    Rivaroxaban
    Maximum Cited Publications
    13 Publications Verification

    BAY 59-7939

    Factor Xa Cardiovascular Disease Cancer
    Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM) .
    Rivaroxaban
  • HY-76948

    Factor Xa Cardiovascular Disease
    5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
    5-R-Rivaroxaban
  • HY-50903S
    Rivaroxaban-d4
    1 Publications Verification

    BAY 59-7939-d4

    Factor Xa Cardiovascular Disease
    Rivaroxaban-d4 is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent,selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM)[1][2].
    Rivaroxaban-d4
  • HY-10264S

    DU-176-d6

    Factor Xa Thrombin Cardiovascular Disease
    Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .
    Edoxaban-d6
  • HY-P4576

    Factor Xa Others
    Methoxycarbonyl-D-Nle-Gly-Arg-pNA is a synthetic trypsin that can serve as a substrate for coagulation factors IXa (FIXa) and Xa (FXa) .
    Methoxycarbonyl-D-Nle-Gly-Arg-pNA
  • HY-10268
    Betrixaban
    3 Publications Verification

    PRT054021

    Factor Xa Cardiovascular Disease
    Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect .
    Betrixaban
  • HY-P2008

    IEGR-AMC

    Factor Xa Cardiovascular Disease
    Boc-Ile-Glu-Gly-Arg-AMC (IEGR-AMC) is an activated factor X (FXa) specific fluorogenic peptide substrate used for Factor VIII determination .
    Boc-Ile-Glu-Gly-Arg-AMC
  • HY-10268B

    PRT054021 hydrochloride

    Factor Xa Cardiovascular Disease
    Betrixaban (PRT054021) hydrochloride is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban hydrochloride shows antithrombotic effect .
    Betrixaban hydrochloride
  • HY-10268A

    PRT054021 maleate

    Factor Xa Cardiovascular Disease
    Betrixaban (PRT054021) maleate is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban maleate shows antithrombotic effect .
    Betrixaban maleate
  • HY-10269

    Factor Xa Cardiovascular Disease
    LY-517717 is a potent and orally active FXa inhibitor. LY-517717 shows antithrombotic and anticoagulant activity. LY-517717 has the potential for the research of venous thromboembolism after hip or knee replacement .
    LY-517717

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: